

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

LISTING OF CLAIMS:

1. (previously presented): An isolated polynucleotide comprising a nucleotide sequence encoding the polypeptide represented by SEQ. ID. No.1.

2. (previously presented): The polynucleotide of Claim 1 comprising the nucleotide sequence set forth in SEQ. ID. No.2.

3. (previously presented): A recombinant polypeptide or its salts comprising the amino acid sequence of SEQ. ID. No.1.

4. (original): A recombinant oncogenic protein comprising an amino acid sequence of SEQ. ID. No.1.

5. (previously presented): A recombinant vector comprising a polynucleotide of Claim 1 or Claim 2.

6. (canceled).

7. (previously presented): A transformed cell produced by transforming a host cell with the recombinant vector of Claim 5.

8. (canceled).

9. (previously presented): A process for producing the recombinant polypeptide of Claim 3 or its salts comprising the steps of:

transforming a host cell with a recombinant vector comprising a polynucleotide encoding the polypeptide represented by SEQ. ID. No. 1, thereby creating a transformed cell;

culturing the transformed cell whereby the transformed cell produces said polypeptide;
and

collecting said recombinant polypeptide from the culture.

10. (previously presented): A process for producing the recombinant oncogenic protein of Claim 4 comprising the steps of:

RESPONSE TO NOTICE TO COMPLY

Application No. 10/758,562

transforming a host cell with a recombinant vector comprising a polynucleotide encoding an oncogenic protein with the amino acid sequence of SEQ. ID. No. 1, thereby creating a transformed cell;

culturing the transformed cell whereby the transformed cell produces said recombinant oncogenic protein; and

collecting said recombinant oncogenic protein from the culture.

11. (previously presented): An antibody generated using the recombinant polypeptide of Claim 3 as an immunogen.

12. (previously presented): The antibody of Claim 11, wherein said antibody is reactive to an epitope of said recombinant polypeptide, and wherein said epitope is within amino acids 623 to 1185 of said recombinant polypeptide.

13. (previously presented): A kit for an antigen-antibody reaction comprising the antibody of Claim 11, wherein said antibody detects an oncogenic protein comprising the amino acid sequence of SEQ. ID. No.1.

14. (previously presented): The kit of claim 13 for detection of an oncogenic protein comprising the amino acid sequence of SEQ. ID. No.1 or a peptide fragment derived from said oncogenic protein, wherein said peptide fragment contains the epitope recognized by said antibody.

15. (previously presented): A polynucleotide comprising a nucleotide sequence complementary to a nucleotide sequence of SEQ. ID. No.2, wherein said polynucleotide has at least a length of 15 to 300 bases.

16. (previously presented): A hybridization kit, comprising the polynucleotide of Claim 15.

17. (previously presented): A kit for detecting expression of mRNA which is translated into an oncogenic protein comprising the amino acid sequence of SEQ. ID. No.1, comprising the polynucleotide of Claim 15.

18. (currently amended): A primer pair for PCR amplification of cDNA comprising the nucleotide sequence of SEQ. ID. No.2, consisting of the following paired primers:

a nucleotide sequence :

RESPONSE TO NOTICE TO COMPLY

Application No. 10/758,562

5'-TTGGATCCATGACATCCAGATTTGGGAAAACATACAGTAGG-3' (**SEQ ID**

NO: 8); and

a nucleotide sequence :

5'-TTGAATTCCTAGCAATGTTCCAAATATTCAATCACTCTAGA-3' (**SEQ ID NO:**

9).

19. (currently amended): A primer pair for PCR amplification of a partial cDNA comprising a nucleotide sequence of SEQ. ID. No.2, consisting of the following paired primers:

5'-GAATTCATAGGCACAGCGCTGAACTGTGTG-3' (**SEQ ID NO: 5)**; and

5'-TTGAATTCCTAGCAATGTTCCAAATATTCA-3' (**SEQ ID NO: 6).**

20. (currently amended): A double strand of short-chain interfering RNA (siRNA) capable of inhibiting expression of a target mRNA in a cervical cancer cell, wherein the siRNA has a nucleotide sequence: CGGACTACCCTTAGCACAA (**SEQ ID NO: 7).**

21. (previously presented): A pharmaceutical composition for inhibiting expression of a target mRNA in a cervical cancer cell to arrest growth of said cell, comprising the siRNA of Claim 20.